anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The vicious crosstalk among capillarization of hepatic sinusoidal endothelial cells (LSECs), activation of hepatic stellate cells (aHSCs), and hepatocyte damage poses a significant impediment to the successful treatment of liver fibrosis. In this study, we propose a sequential combination therapy aimed at disrupting the malignant crosstalk and reshaping the benign microenvironment while repairing damaged hepatocytes to achieve effective treatment of liver fibrosis. Firstly, H-subunit apoferrin (Ferritin) was adopted to load platycodonin D (PLD) and MnO2, forming ferritin@MnO2/PLD (FMP) nanoparticles, which exploited the high affinity of ferritin for the highly expressed transferrin receptor 1 (TfR1) to achieve the precise targeted delivery of FMP in the liver. Upon PLD intervention, restoration of the fenestration pores in capillarized LSECs was facilitated by modulating the phosphatidyl inositol 3-kinase/protein kinase B (PI3K/AKT) and Kruppel Like Factor 2 (KLF2) signaling pathways both in vitro and in vivo, enabling efficient entry of FMP into the Disse space. Subsequently, FMP NPs effectively inhibited HSC activation by modulating the TLR2/TLR4/NF-κB-p65 signaling pathway. Moreover, FMP NPs efficiently scavenged reactive oxygen species (ROS) and mitigated the expression of inflammatory mediators, thereby reshaping the microenvironment to support hepatocyte repair. Finally, administration of bone marrow mesenchymal stem cells (BMMSCs) was employed to promote the regeneration and functional recovery of damaged hepatocytes. In conclusion, the combined sequential therapy involving FMP and BMMSCs effectively attenuated liver fibrosis induced by CCl4 administration, resulting in significant amelioration of the fibrotic condition. The therapeutic strategy outlined in this study underscores the significance of disrupting the deleterious cellular interactions and remodeling the microenvironment, thereby presenting a promising avenue for clinical intervention in liver fibrosis.
Amoxicillin and Clavulanate Potassium Tablets, USP, 250 mg/125 mg: Each film coated tablet, for oral administration, is white, capsule shaped, debossed GGN5 on one side and plain on the reverse side, and contains 250 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt.

Amoxicillin and Clavulanate Potassium Tablets, USP, 500 mg/125 mg: Each film coated tablet, for oral administration, is white, oval-shaped, debossed GGN6 on one side and plain on the reverse side, and contains 500 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt.

Amoxicillin and Clavulanate Potassium Tablets, USP, 875 mg/125 mg: Each film coated tablet, for oral administration, is white, capsule-shaped, scored and debossed GGN7 on one side and scored on the reverse side, and contains 875 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt.

The 250 mg tablet of amoxicillin and clavulanate potassium and the 250 mg chewable tablet should NOT be substituted for each other, as they are not interchangeable and the 250 mg tablet should not be used in children weighing less than 40 kg. The 250 mg tablet of amoxicillin and clavulanate potassium and the 250 mg chewable tablet do not contain the same amount of clavulanic acid. The 250 mg tablet of amoxicillin and clavulanate potassium contains 125 mg of clavulanic acid whereas the 250 mg chewable tablet contains 62.5 mg of clavulanic acid.

Two 250 mg tablets of amoxicillin and clavulanate potassium should NOT be substituted for one 500 mg tablet of amoxicillin and clavulanate potassium. Since both the 250 mg and 500 mg tablets of amoxicillin and clavulanate potassium contain the same amount of clavulanic acid (125 mg, as the potassium salt), two 250 mg tablets of amoxicillin and clavulanate potassium are not equivalent to one 500 mg tablet of amoxicillin and clavulanate potassium.
The invention relates to a traditional Chinese medicinal preparation for treating hysteromyoma, and a preparation method thereof. The traditional Chinese medicinal preparation comprises Smilax scobinicaulis C.H. Wright, Centranthera cochinchinensis, Toxicodendron vernicifluum, Euonymus fortune, Wikstroemia canescens (Wall.) Meissn., cantharis sinica, Alocasia macrorrhiza, herba aristolochiae, Cyperus alternifolius, Polygonum cynanchoides Hemsl., anisetree bark, Bark of Chinese Redbud, Lindera fragrans, Garden Balsam Seed, Cissus modecoides, Root of Shrubberry Rhodiola, Root of Buerger Raspberry, Phlegmariurus austrosinicus (Ching) L. B. Zhang, Corydalis bungeana Turcz., Rhizoma Menispermi, Uncariasessilifructus Roxb., Tricyrtis pilosa Wall and Silene conoidea L.. The traditional Chinese medicinal preparation has the efficacies of invigorating blood circulation and removing blood stasis, moving qi and relieving pains, warming mid-energizer and dispersing cold, softening hardness and dispersing stasis, and eliminating swelling and relieving pains. The preparation method has the characteristics of simplicity, feasibility, safety, effectiveness, and substantial clinic effects.
Induction rates have more than tripled in the last quarter century, and even more in the past five years in light of evidence that the 39th week is the optimal gestational age for birth. Inductions are one of the most commonly performed medical procedures, and may span several days. One of the complications associated with induction include maternal infection, which includes chorioamnionitis, endometritis, pyelonephritis, neonatal infection, perineal and cesarean wound infections. There are many well-known risk factors for these infections that include longer duration of rupture of membrane, prolonged labor, nulliparity, internal monitoring, multiple vaginal examinations and several others. Well-established guidelines are available for treating infection once diagnosed, however the role of antibiotic prophylaxis to prevent infection in patients undergoing induction of labor is less clear. In this study, we propose that administration of 2 grams oral azithromycin prior to the start of induction of labor will decrease rates of intrapartum and postpartum infections. Azithromycin is the ideal antibiotic to study in this trial since it is long acting, inexpensive, well tolerated, and has proven benefits in prior studies for prevention of obstetrical infection in cesarean deliveries and spontaneous labor. This is a double blinded randomized control trial involving administration of 2 grams prophylactic azithromycin in third trimester patients undergoing induction of labor at our institution to demonstrate reduction in maternal and neonatal infection. Decreasing rates of infection will improve both maternal and neonatal outcomes as well as decrease hospital length of stay and associated costs.
A method of making a hyperbranched amphiphilic polyester compound includes drying under vacuum a mixture of 2-(4-hydroxybutyl)-malonic acid and p-toluene sulphonic acid as catalyst. The vacuum is then released with a dry inert gas after drying. The dried mixture is heated under the inert gas at a temperature sufficient for polymerization. The inert gas is evacuated while continuing to heat the mixture. The formed polymer is then dissolved in dimethylformamide and precipitated out by adding methanol. Modifications of the method yield nanoparticles of polyesters having properties suited for coencapsulating fluorescent dyes together with therapeutic drugs, resulting in theranostic nanoparticles, that is, nanoparticles useful in both therapeutic treatments and diagnostic methods.
Participants will take a 0.5 mg fingolimod capsule each day for 3 months. The fingolimod capsule will be placed inside an opaque closed gelatin capsule without transformation of the manufacteror's fingolimod capsule. The fingolimod blinded product and the placebo capsule will be identical in size, color, appearance, and weight.
Following single and multiple oral doses of canagliflozin in patients with type 2 diabetes, dose-dependent decreases in RT Gand increases in urinary glucose excretion were observed. From a starting RT Gvalue of approximately 240 mg/dL, canagliflozin at 100 mg and 300 mg once daily suppressed RT Gthroughout the 24-hour period. Data from single oral doses of canagliflozin in healthy volunteers indicate that, on average, the elevation in urinary glucose excretion approaches baseline by about 3 days for doses up to 300 mg once daily. Maximal suppression of mean RT Gover the 24-hour period was seen with the 300 mg daily dose to approximately 70 to 90 mg/dL in patients with type 2 diabetes in Phase 1 trials. The reductions in RT Gled to increases in mean UGE of approximately 100 g/day in patients with type 2 diabetes treated with either 100 mg or 300 mg of canagliflozin. In patients with type 2 diabetes given 100 to 300 mg once daily over a 16-day dosing period, reductions in RT Gand increases in urinary glucose excretion were observed over the dosing period. In this trial, plasma glucose declined in a dose-dependent fashion within the first day of dosing. In single-dose trials in healthy and type 2 diabetic patients, treatment with canagliflozin 300 mg before a mixed-meal delayed intestinal glucose absorption and reduced postprandial glucose. 

Cardiac Electrophysiology

In a randomized, double-blind, placebo-controlled, active-comparator, 4-way crossover trial, 60 healthy subjects were administered a single oral dose of canagliflozin 300 mg, canagliflozin 1,200 mg (4 times the maximum recommended dose), moxifloxacin, and placebo. No meaningful changes in QTc interval were observed with either the recommended dose of 300 mg or the 1,200 mg dose.
LINZESS® 290 μg capsules, orally, once daily for up to 52 weeks for participants with IBS-C. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
PURPOSE:To obtain a mineral supply agent useful as a natural food additive, containing no organic substance prepared by burning a whey concentrate. CONSTITUTION:A whey mineral concentrate is burnt at 500-1,200 deg.C for 1-5 hours to give a mineral supply agent containing no organic substance. A whey mineral concentrate concentrated to >=70% ash content in the dried material is used as the whey mineral concentrate. Well-known ion exchange method, electrophoresis method, get filtration method, ultrafiltration method, precipitation recovery method, etc., may be cited as the concentrating means. Since the whey mineral concentrate necessarily contains an organic substance, the concentrate has a color, a fragrance and a flavor derived from the raw material and damages flavor, transparency, color tone, etc., of target foods to which the concentrate is added and causes problems of safety resulting from admixture of agricultural chemical, change with time during preservation and browning during processing under heating. The mineral supply agent is excellent as a natural additive of Ca or K and readily usable because of neutrality of aqueous solution.
PURPOSE:To obtain a skin cosmetic, containing a high-molecular weight silicone and a low-boiling oil for dissolving the silicone, having good extensibility as well as refreshing feeding with hardly any sticking to contact materials and capable of particularly protecting the skin from skin roughening by scrubbing and washing work, etc., for a long period. CONSTITUTION:A skin cosmetic containing 1-30wt.% compound expressed by the formula (R1 is methyl or partially phenyl; R2 is methyl or OH; n is 3,000-20,000) and 10-80wt.% low-boiling oil in an amount required for dissolving the above-mentioned compound. Low-boiling silicone, e.g. cyclic silicone such as octamethylcyclotetrasiloxane, etc., low-boiling chain silicone such as dimethylpolysiloxane, etc., 1-30C isoparaffinic hydrocarbon, etc., are used as the low-boiling oil in an amount of preferably 1-50 times based on the high-molecular weight silicone. The above-mentioned skin cosmetic will not lose protecting effects even by repeating washing with water. A surfactant and water-soluble polyhydric alcohol may be added for use as an emulsified cosmetic.
Fine inhalable particulate matter (PM) triggers an inflammatory response in the airways and activates mononuclear cells, mediators of tissue homeostasis, and tumour-promoting inflammation. We have assessed ex vivo responses of human monocytes and monocyte-derived macrophages to standardised air pollutants: carbon black, urban dust, and nanoparticulate carbon black, focusing on their pro-inflammatory and DNA-damaging properties. None of the PM (100 μg/mL/24 h) was significantly toxic to the cells, aside from inducing oxidative stress, fractional DNA damage, and inhibiting phagocytosis. TNFα was only slightly increased. PM nanoparticles increase the expression and activate DNA-damage-related histone H2A.X as well as pro-inflammatory NF-κB. We have shown that the urban dust stimulates the pathway of DNA damage/repair via the selective post-translational phosphorylation of H2A.X while nanoparticulate carbon black increases inflammation via activation of NF-κB. Moreover, the inflammatory response to lipopolysaccharide was significantly stronger in macrophages pre-exposed to urban dust or nanoparticulate carbon black. Our data show that airborne nanoparticles induce PM-specific, epigenetic alterations in the subsets of cultured mononuclear cells, which may be quantified using binary fluorescence scatterplots. Such changes intercede with inflammatory signalling and highlight important molecular and cell-specific epigenetic mechanisms of tumour-promoting inflammation.
Participants in this arm will be offered 2 education sessions with a certified asthma educator in the clinic at start of the study and again at 6-months. These sessions will be followed by a telephone call from the certified asthma educator several weeks after the sessions.
Eating disorders (EDs) are among the deadliest of all psychiatric disorders. However, first-line treatments for EDs are effective for only roughly 40% of adolescent patients. One barrier to treatment efficacy is the persistence of driven exercise (DEx; exercising in a compulsive manner to control weight and/or regulate emotion), a hallmark symptom reported among many adolescents diagnosed with restrictive EDs (59-73%). Among other negative sequelae, DEx is associated with suicidal behavior, poorer treatment outcome, increased comorbid psychopathology, and risk for relapse. Further, while multiple eating-related tasks have been validated that discriminate between individuals with EDs and healthy populations, there are currently no well-validated tasks that directly assess sensitivity and responsivity to exercise in ED populations. As DEx is a poorly understood symptom that plays a key role in ED maintenance, investigating its biobehavioral underpinnings is of critical importance. Existing research points towards both reward and threat functions of exercise, which may drive and perpetuate DEx among those with EDs. Evaluation of both reward and threat functions of exercise among those with EDs will improve mechanistic understanding of this ED feature; ultimately, improved understanding of DEx will inform treatment targets. The proposed project will recruit adolescent and young adult females (16-25y) with (n = 67) and without (n = 33) EDs from two sites to participate in a comprehensive evaluation of acute exercise response. The current project will 1) characterize variability in biobehavioral response to in-lab exposure to moderate-intensity exercise among those with and without EDs; 2) create and refine tasks that capture engagement of reward- and threat-related systems during exercise; and 3) test hypotheses that acute exercise response is more pronounced among individuals with EDs and that acute exercise response relates to ED symptom severity, DEx, and free-living activity. Detailed explication of acute exercise effects among individuals with EDs in a controlled setting will have significant impact on the empirical study of EDs, specifically to (i) improve assessment of DEx risk and function (ii) elucidate a testable model of DEx risk and (iii) suggest targets for DEx intervention. The methods validated in this project will improve understanding of DEx, a treatment- resistant ED feature. These methods will also lay the groundwork for larger-scale, clinical research which clarifies optimal targets for DEx in ED treatment.
Coated microparticle capsules comprise at least an active principle (AP) covered by at least two distinct film coatings and have an average diameter of lower than 2000 microns, preferably 100-600 microns. The film coatings, in combination, are able: to release AP by two different trigger mechanisms, one based on a variation of pH and the other allows the AP release at the end of a predetermined residential time in the stomach; and to induce an in vitro dissolution behavior. Coated microparticle capsules comprise at least an active principle (AP) covered by at least two distinct film coatings and have an average diameter of lower than 2000 microns, preferably 100-600 microns. The film coatings, in combination, are able: to release AP by two different trigger mechanisms, one based on a variation of pH and the other allows the AP release at the end of a predetermined residential time in the stomach; and to induce an in vitro dissolution behavior (determined as indicated in the dissolutest in European Pharmacopeia 5.2 or type II apparatus in the US Pharmacopeia 28-NF23 maintained at 37[deg]C and agitated at 100 rpm). The in vitro dissolution behavior of the microcapsules is such that, at a constant pH of 1.4, a latency phase =8 hours, preferably 1-5 hours is observed and the change from pH 1.4 to pH 7.1, results in a prolonged release phase of the AP that starts without a latency period such as the t1/2 i.e. duration necessary to release 50% of PA contained in the coated microparticles, being 0.25-20 hours, preferably 0.25-4 hours. Independent claims are included for: (1) microparticles coated with (A) and (T); and (2) a pharmaceutical, veterinary or dietetic formulation, comprising numerous coated microparticles, preferably 5000-500000 microparticles.
Primary bone tumors in children and adolescents, while rare, pose significant challenges in diagnosis and management. Children treated for Ewing sarcoma and osteosarcoma are offered a 5-year follow-up program after end of treatment, including radiological surveillance of primary location of tumor and the lungs. There is no consensus regarding how often and how the children should be followed with radiological imaging. This retrospective descriptive study of 69 patients (34 with Ewing sarcoma and 35 with osteosarcoma) investigated the consequences of abnormal findings in 1279 follow-up images. Nine relapses were detected, 4 in the Ewing group (3 local and 1 pulmonary) and 5 in the osteosarcoma group (1 local and 4 pulmonary). Of these, only two patients exhibited symptomatic relapses, with the remainder identified through imaging. The positive predictive value for relapse detection was 0.44 in the Ewing group, and 0.5 in the osteosarcoma group. In the Ewing sarcoma patient image follow-up program, the probability of anomaly detection was 12% (95% CI, 10-15). For osteosarcoma patients, the likelihood was 6% (95% CI, 4-8). Our data indicates that abnormal findings on follow-up images rarely represents relapse of tumor. As the surveillance protocol differs between the patient groups, wherein Ewing sarcoma patients primarily are monitored through MRI while osteosarcoma patients are predominantly tracked via X-rays, there is an increased occurrence of incidental findings in the first group. However, it is imperative to interpret imaging data in conjunction with clinical information, avoiding isolated reliance on imaging results when making treatment decisions.
The process for preparation and quantification of the polysaccharide complex from the spotted hemlock consists in aqueous extraction of the raw material (1:1) at the temperature up to 95 DEGREE C for 1 hour with continuous mixing. The raw material is separated by centrifugation. The combined extracts are stripped to 1/5 of the initial volume of the raw material. The polysaccharide complex is precipitated with 96% ethanol at the room temperature at a 3:1 ratio. The precipitate is filtered, washed with 96% ethanol, acetone, dried and weighed. The polysaccharide content is assayed gravimetrically after fractionation with 95% ethanol followed by the hydrolysis of polysaccharides with the sulfuric acid (1 mol/l) at the temperature of 100+- 2.5 DEGREE C. Monosaccharides are identified by paper, thin-layer and gas-liquid chromatography.
Background and Objectives: Total knee arthroplasty (TKA) has become the treatment of choice for advanced osteoarthritis. The aim of this paper was to show the possibilities of optimizing the Perth CT protocol, which is highly effective for preoperative planning and postoperative assessment of alignment. Materials and Methods: The cross-sectional study comprised 16 patients for preoperative planning or postoperative evaluation of TKA. All patients were examined with the standard and optimized Perth CT protocol using advance techniques, including automatic exposure control (AEC), iterative image reconstruction (IR), as well as a single-energy projection-based metal artifact reduction algorithm for eliminating prosthesis artifacts. The effective radiation dose (E) was determined based on the dose report. Imaging quality is determined according to subjective and objective (values of signal to noise ratio (SdNR) and figure of merit (FOM)) criteria. Results: The effective radiation dose with the optimized protocol was significantly lower compared to the standard protocol (p < 0.001), while in patients with the knee prosthesis, E increased significantly less with the optimized protocol compared to the standard protocol. No significant difference was observed in the subjective evaluation of image quality between protocols (p > 0.05). Analyzing the objective criteria for image quality optimized protocols resulted in lower SdNR values and higher FOM values. No significant difference of image quality was determined using the SdNR and FOM as per the specified protocols and parts of extremities, and for the presence of prothesis. Conclusions: Retrospecting the ALARA ('As Low As Reasonably Achievable') principles, it is possible to optimize the Perth CT protocol by reducing the kV and mAs values and by changing the collimation and increasing the pitch factor. Advanced IR techniques were used in both protocols, and AEC was used in the optimized protocol. The effective dose of radiation can be reduced five times, and the image quality will be satisfactory.
PURPOSE:To obtain the subject compound having skin-beautifying action and useful as an active component of a skin-beautifying external drug such as face lotion and pack at a low cost by extracting root sheath of mulberry with a water-containing hydrophilic organic solvent. CONSTITUTION:The objective compound can be produced by extracting root sheath of mulberry with a water-containing hydrophilic organic solvent. Concretely, the root sheath of mulberry is crushed and cut into small pieces and extracted with a mixture of water and a hydrophilic organic solvent such as methanol. The ratio of the organic solvent in the extraction solvent is >=50%, preferably about 70-95%. About 5-15 pts. of the extraction solvent is added to 1 pt. of the root sheath and heated under refluxing or left to rest at normal temperature or under heating. The solvent is distilled off from the obtained extracted liquid and the residue is dissolved in about 10-100 times volume of water. The solution is passed through a column packed with a synthetic polymer adsorbent having a macro-network structure to obtain the objective compound.